← Back to headlines
Eli Lilly Capitalizes on Demand for Weight Loss Drugs, Valuation Remains Compelling
Eli Lilly is benefiting from strong consumer demand for its weight loss drugs, with analyst Gary Black suggesting the company's valuation remains compelling.
3 May, 12:01 — 3 May, 12:01
Sources
Showing 1 of 1 sources
